BioAtla, Inc.

$3.62-6.46%($-0.25)
TickerSpark Score
46/100
Weak
50
Valuation
60
Profitability
55
Growth
36
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCAB research report →

52-Week Range1% of range
Low $3.26
Current $3.62
High $71.50

Companywww.bioatla.com

BioAtla, Inc. , a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

CEO
Jay Short
IPO
2020
Employees
61
HQ
San Diego, CA, US

Price Chart

-81.51% · this period
$61.00$32.31$3.62May 20Nov 18May 20

Valuation

Market Cap
$4.56M
P/E
-0.11
P/S
2.28
P/B
-0.15
EV/EBITDA
-0.18
Div Yield
0.00%

Profitability

Gross Margin
105.95%
Op Margin
-2524.95%
Net Margin
-2530.85%
ROE
166.67%
ROIC
477.89%

Growth & Income

Revenue
$2.00M · -81.82%
Net Income
$-59,607,000 · 14.57%
EPS
$-50.50 · 29.86%
Op Income
$-59,305,000
FCF YoY
32.99%

Performance & Tape

52W High
$71.50
52W Low
$3.26
50D MA
$5.85
200D MA
$22.17
Beta
0.79
Avg Volume
38.88K

Get TickerSpark's AI analysis on BCAB

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 10, 26Sievers Ericother240,000
Mar 11, 26SHORT JAY M PHDother430,000
Mar 10, 26Vasquez Christianother240,000
Feb 28, 26SHORT JAY M PHDother7,728
Feb 28, 26Vasquez Christianother1,802
Feb 28, 26WALDRON RICHARD Aother2,729
Feb 28, 26Sievers Ericother3,140
Nov 30, 25WALDRON RICHARD Aother2,371
Nov 30, 25Sievers Ericother2,729
Nov 30, 25SHORT JAY M PHDother6,347

Our BCAB Coverage

We haven't published any research on BCAB yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate BCAB Report →

Similar Companies